- Home
- OKE vs ZTS Comparison
OKE vs ZTS Comparison
Compare OKE & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OKE | ZTS |
|---|---|---|
| Founded | 1906 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.8B | 54.8B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | OKE | ZTS |
|---|---|---|
| Price | $78.03 | $124.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | $90.00 | ★ $166.60 |
| AVG Volume (30 Days) | 3.7M | ★ 4.3M |
| Earning Date | 02-23-2026 | 02-12-2026 |
| Dividend Yield | ★ 5.49% | 1.71% |
| EPS Growth | ★ 13.61 | 11.64 |
| EPS | 5.43 | ★ 5.94 |
| Revenue | ★ $31,564,000,000.00 | $9,397,000,000.00 |
| Revenue This Year | $52.55 | $3.04 |
| Revenue Next Year | $8.52 | $4.96 |
| P/E Ratio | ★ $14.37 | $20.90 |
| Revenue Growth | ★ 58.35 | 2.68 |
| 52 Week Low | $64.02 | $115.25 |
| 52 Week High | $107.50 | $177.40 |
Technical Indicators
Market Signals| Indicator | OKE | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 63.79 | 46.60 |
| Support Level | $72.42 | $121.65 |
| Resistance Level | $76.73 | $127.12 |
| Average True Range (ATR) | 2.03 | 2.98 |
| MACD | 0.50 | -0.27 |
| Stochastic Oscillator | 78.84 | 24.74 |
Price Performance
Historical ComparisonAbout OKE ONEOK Inc.
Oneok is a diversified midstream service provider specializing in natural gas gathering, processing, storage, and transportation and natural gas liquids transportation and fractionation. It also operates a refined product and crude oil segment connecting producers, refiners, and consumers. Operations are in the midcontinent, Permian, and Rocky Mountain regions.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.